Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modulation of SLFN11 induces changes in DNA Damage response in breast cancer

24 Nov 2023

Abstract excerpt

BACKGROUND: Lack of Schlafen family member 11 (SLFN11) expression has been recently identified as a dominant genomic determinant of response to DNA damaging agents in numerous cancer types. Thus, several strategies aimed at increasing SLFN11 are explored to restore chemosensitivity of refractory cancers. In this study, we examined various approaches to elevate SLFN11 expression in breast cancer cellular models...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer Immunotherapy and Biomarkers
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38001424
DOI: 10.1186/s12935-023-03144-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modulation of SLFN11 induces changes in DNA Damage response in breast cancerPMID 38001424Read ↗

Modulation of SLFN11 induces changes in DNA Damage responseSemantic proximity Read ↗

Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapySemantic proximity Read ↗

SLFN11 is a general target for enhancing the sensitivity of cancer to chemotherapy (DNA-damaging agents)Semantic proximity Read ↗

SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidanceSemantic proximity Read ↗

SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in ovarian cancerSemantic proximity Read ↗

SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killingSemantic proximity Read ↗

Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1BSemantic proximity Read ↗

Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway ActivitySemantic proximity Read ↗

The Role of IRF9 Upregulation in Modulating Sensitivity to Olaparib and Platinum-Based Chemotherapies in Breast CancerSemantic proximity Read ↗

Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsSemantic proximity Read ↗

DNA methylation status of key cell-cycle regulators such as CDKNA2/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors.Semantic proximity Read ↗

The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.